Literature DB >> 906217

An evaluation of chemical restraining agents in the horse.

G MacKenzie, D H Snow.   

Abstract

An evaluation of acepromazine (0.5 mg/kg intramuscularly), azaperone (0.7 and 0.9 mg/kg intramuscularly) and xylazine (2.0 mg/kg intramuscularly) as chemical restraining agents was carried out in seven horses. (Xylazine and azaperone were used at the recommended dose rates; acepromazine at five times the recommended dose rates). Of the three drugs administered only azaperone produced sufficient sedation in all the horses to allow a percutaneous needle muscle biopsy to be taken from six muscles. With acepromazine and xylazine this procedure could be successfully carried out in five and four horses respectively. Both acepromazine and azaperone produced a mild transient tachycardia and a fall in packed cell volume but all three drugs reduced the "stress" of muscle biopsy as measured by increases in heart rate. Azaperone produced an increase in plasma 11-OHCS levels when administered to control animals. The measurement of changes in plasma 11-OHCS levels was not found to be a satisfactory means of assessing any reduction of "stress" with some sedative agents.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 906217     DOI: 10.1136/vr.101.2.30

Source DB:  PubMed          Journal:  Vet Rec        ISSN: 0042-4900            Impact factor:   2.695


  2 in total

1.  Determination of a sedative dose and influence of droperidol and midazolam on cardiovascular function in pigs.

Authors:  R Bustamante; A Valverde
Journal:  Can J Vet Res       Date:  1997-10       Impact factor: 1.310

2.  Ameliorating the adverse cardiorespiratory effects of chemical immobilization by inducing general anaesthesia in sheep and goats: implications for physiological studies of large wild mammals.

Authors:  Adian Izwan; Edward P Snelling; Roger S Seymour; Leith C R Meyer; Andrea Fuller; Anna Haw; Duncan Mitchell; Anthony P Farrell; Mary-Ann Costello; Shane K Maloney
Journal:  J Comp Physiol B       Date:  2018-09-19       Impact factor: 2.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.